{"transactions":[{"id":679553,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:07:50.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":604,"price":2.01,"value":1214.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":146349,"source":{"system":"sec-edgar","filing":"0000905148-26-003837","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003837/form4.xml","form_type":"4"}},{"id":769398,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:31.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":72981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":146953,"source":{"system":"sec-edgar","filing":"0000905148-26-002550","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002550/form4.xml","form_type":"4"}},{"id":774265,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:10:39.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":1.92,"value":1176.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":73972,"source":{"system":"sec-edgar","filing":"0000905148-26-002499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002499/form4.xml","form_type":"4"}},{"id":864765,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:16:29.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":186728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":186728,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":186728},"source":{"system":"sec-edgar","filing":"0000905148-26-001116","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001116/form4.xml","form_type":"4"}},{"id":895590,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:10:45.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":1.63,"value":1178.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":74585,"source":{"system":"sec-edgar","filing":"0000905148-26-000935","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000935/form4.xml","form_type":"4"}},{"id":938272,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:38:05.000Z","date":"2026-01-13","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.7218,"value":17218.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4."}],"balance_after":75308,"source":{"system":"sec-edgar","filing":"0000905148-26-000212","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000212/form4.xml","form_type":"4"}},{"id":994996,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:29:50.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":2.24,"value":1373.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":65308,"source":{"system":"sec-edgar","filing":"0000905148-25-004128","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004128/form4.xml","form_type":"4"}},{"id":1063469,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-18T21:15:52.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":1.39,"value":852.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":65921,"source":{"system":"sec-edgar","filing":"0000905148-25-003040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003040/form4.xml","form_type":"4"}},{"id":1144659,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-16T20:17:04.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":1.14,"value":698.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":66534,"source":{"system":"sec-edgar","filing":"0000905148-25-001821","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001821/form4.xml","form_type":"4"}},{"id":1225881,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T22:21:46.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":140540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":140540,"derivative":{"exercise_price":5.31,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":140540},"source":{"system":"sec-edgar","filing":"0000905148-25-000834","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000834/form4.xml","form_type":"4"}},{"id":1258469,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:53:37.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":724,"price":5.42,"value":3924.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":67147,"source":{"system":"sec-edgar","filing":"0000905148-25-000726","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825000726/form4.xml","form_type":"4"}},{"id":1348788,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T23:06:09.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":90090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":90090,"derivative":{"exercise_price":5.7,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":90090},"source":{"system":"sec-edgar","filing":"0000905148-24-003289","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003289/form4.xml","form_type":"4"}},{"id":1361253,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-11-18T21:28:58.000Z","date":"2024-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":7.92,"value":4854.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":67871,"source":{"system":"sec-edgar","filing":"0000905148-24-003224","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824003224/form4.xml","form_type":"4"}},{"id":1430835,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-16T20:48:59.000Z","date":"2024-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":7.02,"value":4303.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":68484,"source":{"system":"sec-edgar","filing":"0000905148-24-002278","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824002278/form4.xml","form_type":"4"}},{"id":1506590,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T20:04:32.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":86615,"derivative":{"exercise_price":1.04,"expiration_date":"2031-01-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000905148-24-001566","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824001566/form4.xml","form_type":"4"}},{"id":1506589,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-21T20:04:32.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":1.04,"value":10400.0,"ownership":{"direct":true},"balance_after":69097,"source":{"system":"sec-edgar","filing":"0000905148-24-001566","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824001566/form4.xml","form_type":"4"}},{"id":1513693,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-16T22:56:28.000Z","date":"2024-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":8.36,"value":5124.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":59097,"source":{"system":"sec-edgar","filing":"0000905148-24-001485","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824001485/form4.xml","form_type":"4"}},{"id":1637423,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-16T22:08:36.000Z","date":"2024-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":3.4,"value":2458.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":59710,"source":{"system":"sec-edgar","filing":"0000905148-24-000761","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824000761/form4.xml","form_type":"4"}},{"id":1738557,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-11-17T00:41:32.000Z","date":"2023-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2450,"price":5.08,"value":12446.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":60433,"source":{"system":"sec-edgar","filing":"0000905148-23-001473","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514823001473/form4.xml","form_type":"4"}},{"id":1864804,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T20:15:49.000Z","date":"2023-06-05","kind":"exercise","planned":false,"acquired":false,"shares":9225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":96615,"derivative":{"exercise_price":1.04,"expiration_date":"2031-01-13","underlying":"Common Stock","underlying_shares":9225},"source":{"system":"sec-edgar","filing":"0001140361-23-028539","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000114036123028539/form4.xml","form_type":"4"}},{"id":1864803,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-06-06T20:15:49.000Z","date":"2023-06-05","kind":"exercise","planned":false,"acquired":true,"shares":9225,"price":1.04,"value":9594.0,"ownership":{"direct":true},"balance_after":62883,"source":{"system":"sec-edgar","filing":"0001140361-23-028539","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000114036123028539/form4.xml","form_type":"4"}},{"id":2114019,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T00:18:09.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":100150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":100150,"derivative":{"exercise_price":12.5,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":100150},"source":{"system":"sec-edgar","filing":"0001209191-22-057399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057399/doc4.xml","form_type":"4"}},{"id":2114018,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-17T00:18:09.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":33383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":53658,"source":{"system":"sec-edgar","filing":"0001209191-22-057399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057399/doc4.xml","form_type":"4"}}]}